- Home
- PNI vs VNRX Comparison
PNI vs VNRX Comparison
Compare PNI & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PNI
- VNRX
- Stock Information
- Founded
- PNI 2002
- VNRX N/A
- Country
- PNI United States
- VNRX United States
- Employees
- PNI N/A
- VNRX N/A
- Industry
- PNI Trusts Except Educational Religious and Charitable
- VNRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PNI Finance
- VNRX Health Care
- Exchange
- PNI Nasdaq
- VNRX Nasdaq
- Market Cap
- PNI 77.2M
- VNRX 64.8M
- IPO Year
- PNI N/A
- VNRX N/A
- Fundamental
- Price
- PNI $6.95
- VNRX $0.62
- Analyst Decision
- PNI
- VNRX Strong Buy
- Analyst Count
- PNI 0
- VNRX 4
- Target Price
- PNI N/A
- VNRX $3.50
- AVG Volume (30 Days)
- PNI 26.4K
- VNRX 192.3K
- Earning Date
- PNI 01-01-0001
- VNRX 11-13-2025
- Dividend Yield
- PNI 4.76%
- VNRX N/A
- EPS Growth
- PNI N/A
- VNRX N/A
- EPS
- PNI N/A
- VNRX N/A
- Revenue
- PNI N/A
- VNRX $1,319,252.00
- Revenue This Year
- PNI N/A
- VNRX $399.39
- Revenue Next Year
- PNI N/A
- VNRX $242.09
- P/E Ratio
- PNI N/A
- VNRX N/A
- Revenue Growth
- PNI N/A
- VNRX 35.10
- 52 Week Low
- PNI $6.03
- VNRX $0.40
- 52 Week High
- PNI $7.89
- VNRX $0.94
- Technical
- Relative Strength Index (RSI)
- PNI 73.75
- VNRX 45.32
- Support Level
- PNI $6.49
- VNRX $0.57
- Resistance Level
- PNI $6.93
- VNRX $0.73
- Average True Range (ATR)
- PNI 0.07
- VNRX 0.05
- MACD
- PNI 0.03
- VNRX -0.00
- Stochastic Oscillator
- PNI 90.49
- VNRX 33.69
About PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.